Full Year 2019 Sun Pharmaceutical Industries Ltd Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst : Sir, first on Ilumya. Could you give us some color on how the formulary coverage is panning out for the drug?

Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst : Sir, given that we've seen more launches in IL-23, doesn't formulary coverage become important? I understand the medical benefit, but wouldn't that, therefore, become more important with the launch of more IL-23s?

Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst : Understood. And sir, my second question is the direct-to-consumer program that we've launched. Has that significantly helped the prescriptions after we have launched that program? I am just trying to understand, let's assume we discontinue that program, is there a risk that the prescriptions fall off? Have we seen a very sharp improvement after this program or that will be gradual, we'll get to know after a couple of months?

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : Sir, on Ilumya, on the additional indication clinical trials, what is the thought process in terms of going forward on that?

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : On the Ilumya -- for Ilumya, the additional -- clinical trials for the additional indications, is there -- I mean, just wanted to understand the thought process in terms of how we are looking to approach it now?

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : But I mean, most of the lead -- the existing guys have multiple indications. Is that a handicap when we sort of go out and market the product?

Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst : That's helpful. And secondly, on Odomzo, how has -- any sort of updates on how the program -- the molecule -- the product has progressed for the year?

Question: Rahul Sharma - KARVY Stock Broking Limited, Research Division - Analyst : Just I wanted to reconfirm as -- should we take the adjusted sales for March '19 as the base for our future forecast?

Question: Rahul Sharma - KARVY Stock Broking Limited, Research Division - Analyst : Okay. I missed out that. What is the total guidance for the year?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : My question pertains to U.S. sales manufacturing for 6 months. Can you give the product names?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. And my second question pertains to the R&D investment. What is the range of investments that you see over the next 2 to 3 years?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. And next year? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. MAY 28, 2019 / 1:00PM, SUNPHARMA.NSE - Full Year 2019 Sun Pharmaceutical Industries Ltd Earnings Call

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. And do you expect any rationalization of products in the U.S. and in India?